The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012
| Autor: | David Horn, Shun-Ping Quan, Nkechi Azie, Herwig Ulf Meier-Kriesche, Dionissios Neofytos, Michael A. Pfaller |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Microbiological Techniques
Microbiology (medical) Voriconazole medicine.medical_specialty Antifungal Agents International Cooperation Mortality rate General Medicine Biology Aspergillosis medicine.disease Survival Analysis Infectious Diseases Mycoses Acquired immunodeficiency syndrome (AIDS) Internal medicine North America Epidemiology medicine Humans Intensive care medicine Survival rate Fluconazole Survival analysis medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 73:293-300 |
| ISSN: | 0732-8893 |
| DOI: | 10.1016/j.diagmicrobio.2012.06.012 |
| Popis: | The Prospective Antifungal Therapy Alliance (PATH Alliance®) performed prospective surveillance of invasive fungal infections (IFIs) among patients hospitalized at 25 medical centers in North America between 2004 and 2008, collecting information on the epidemiology, diagnosis, treatment, and mortality rates of IFIs. In total, 7526 IFIs were identified in 6845 patients. Candida spp. (73.4%) were the most common pathogens, followed by Aspergillus spp. (13.3%), and other yeasts (6.2%). Culture was the most frequently used diagnostic test in the majority of IFI categories. Most patients with invasive candidiasis were treated with fluconazole (48.3%) and the echinocandins (34.0%), while voriconazole (45.5%) was the main antifungal agent for invasive aspergillosis. The 12-week survival rate ranged from 37.5% for hematopoietic stem cell transplant recipients to ~75.0% for those with HIV/AIDS. In summary, the findings of the PATH Alliance® registry provide a better understanding of the epidemiology of a vast variety and large numbers of IFIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect